Transition Therapeutics Inc (NASDAQ:TTHI)
| 3.51 Data as of Jun 18 |  -0.033 / -0.93%Today’s Change | 1.78 Today|||52-Week Range 3.84 | +55.18% Year-to-Date |
Latest TTHI News | Press Releases
| Is Elan Pushing Its Luck? Jun 18 / MotleyFool.com | Eli Lilly to Take Over Development of Diabetes Drug Jun 17 / MotleyFool.com |
Today’s Trading
| Previous close | 3.54 |
| Today’s open | 3.54 |
| Day’s range | -- - -- |
| Volume | 27,742 |
| Average volume (3 months) | 78,592 |
| Market cap | $95.3M |
| Dividend yield | -- |
Data as of 3:59pm ET, 06/18/2013
Growth & Valuation
| Earnings growth (last year) | -185.55% |
| Earnings growth (this year) | +93.05% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -100.00% |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | 3.02 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LPDXLipoScience Inc | +0.05 | +0.75% |
| TROVTrovagene Inc | +0.02 | +0.31% |
| PATHNupathe Inc | +0.01 | +0.36% |
| GALTGalectin Therapeutic... | -0.18 | -4.33% |
Data as of 4:00pm ET, 06/18/2013
Financials
| Next reporting date | September 30, 2013 |
| EPS forecast (this quarter) | -$0.11 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$12.2M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Tony F. Cruz, PhD |
Chief Financial Officer Nicole Rusaw-George |
Corporate headquarters Toronto, Ontario |
Forecasts
